Why the study?
This review was conducted to examine whether colchicine's reduction in ischemic events translates to reduced mortality, determine optimal treatment duration, and identify which patient populations benefit most.
Does low-dose colchicine reduce cardiovascular events in patients with coronary artery disease?
Does low-dose colchicine reduce cardiovascular events in patients with coronary artery disease?
Low-dose colchicine is an effective, cost-efficient, and well-tolerated therapy for the secondary prevention of atherothrombotic events in patients with coronary artery disease.
Supports the use of colchicine for secondary prevention in coronary heart disease; extends prior randomized data by clarifying.
PURPOSE: This review of colchicine, an effective anti-inflammatory agent, examines whether the reduction in ischemic events produced by colchicine translates to a reduction in mortality, the optimal duration of treatment, and the patient populations that benefits the most from colchicine treatment. METHODS: We performed a comprehensive PubMed database search using the key words colchicine and coronary heart disease on August 23, 2021. We also screened the included reference list of manuscripts. FINDINGS: Colchicine's role in the secondary prevention of coronary artery disease has been the focus of recent large-scale randomized controlled trials in chronic coronary syndrome (ie, the Low-Dose Colchicine and Low-Dose Colchicine 2 trials), acute myocardial infarction (the Colchicine Cardiovascular Outcomes Trial and Colchicine in Patients With Acute Coronary Syndrome trial), and after percutaneous coronary intervention (the Colchicine-Percutaneous Coronary Intervention trial). IMPLICATIONS: Current evidence suggests that low-dose colchicine (0.5 mg once a day) reduces the risk of cardiovascular events among patients with acute myocardial infarction or chronic coronary syndrome. Colchicine has the potential to become a new standard therapy for the prevention of coronary artery disease-related atherothrombotic events because it is effective and cost-efficient and has a well-tolerated safety profile.
No takes yet. Share an insight, caveat, or question.
Yong et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: